Author

Meixia Chen

Observed names: Chen, Meixia, M. M. Shangzhong Chen

Institution: Haisco Pharmaceutical Group Co., Ltd. (China)

Observed institutions: Zhejiang Hospital, Haisco Pharmaceutical Group Co., Ltd. (China)

ORCID: 0000-0002-7328-058X

Observed ORCID: 0000-0002-7328-058X

OpenAlex ID: A5061852162

Pharmacokinetics and exposure–safety relationship of ciprofol for sedation in mechanically ventilated patients in the intensive care unit

2024 · Lu Liu, Kun Wang, et al. · CPT Pharmacometrics & Systems Pharmacology · 15

Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study

2025 · Yuhao Wang, Chao Yu, et al. · British Journal of Clinical Pharmacology · 10

Population pharmacokinetic modeling and exposure-response analysis of anrikefon: insights and implications in clinical analgesia

2025 · Kun Wang, Meixia Chen, et al. · Expert Review of Clinical Pharmacology · 7

Association between RBC transfusion and 1-year mortality in ICU survivors

2022 · M. M. Shangzhong Chen, M. M. Huojun Jiang, et al. · Critical Care · 2

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of HSK39297 in Chinese Healthy Subjects: A Phase 1 Clinical Trial

2025 · Yuyang Dai, Feng Wu, et al. · Clinical and Translational Science

Works count: 6

Citation count: 34

H-index: 3

I10-index: 2